A novel treatment option for schizophrenia

Psychopharm Review

Volumn 45, Issue 1, 2010, Pages 1-6

  Rado, Jeffrey ^a   Janicak, Philip G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FANAPT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; ILOPERIDONE; PLACEBO; RISPERIDONE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGITATION; AKATHISIA; ANXIETY; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 78649368022     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.idt.0000365317.93432.c1     Document Type: Review

References (10)

1. Yan J. FDA reverses earlier decision, approves schizophrenia drug. Psychiatr News 2009;44(11):2.
2. Ichikawa J, Li Z, Dai J, et al. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956:349-357.
3. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broadspectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-914.
4. Subramanian N, Kalkman HO. Receptor profile of P88- 8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:553-560.
5. Potkin SG, Litman RE,Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28:S4-S11.
6. Cutler AJ, Kalali AH,Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2) (suppl 1):S20-S28.
7. Cutler AJ, Bishop JR. An update on the investigational antipsychotic iloperidone: an expert interview with Andrew J. Cutler, MD. Medscape Psychiatry Ment Health 2008. Available at: http://medscape.com/ viewarticle/571878.
8. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2)(suppl 1):S29-S35).
9. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70(6):801-809.
10. Weiden PJ, CutlerAJ, PolymeropoulosMH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2)(suppl 1):S12-S19.